India’s Precision Medicine: A Vision Hindered by Biobank Regulations

Precision medicine, a transformative approach to healthcare, is redefining the landscape of disease diagnosis and treatment. From groundbreaking personalised healthcare solutions to innovations like mRNA vaccines and gene-editing technologies, the field promises a new era in medical science. Yet, as India stands on the cusp of this revolution, a significant hurdle looms: the lack of robust biobank regulations.

Organ-on-chip device Biobanks, essential repositories of biological samples, are critical to the success of precision medicine. These collections of blood, DNA, and tissue samples, coupled with genetic data, form the backbone of research aimed at developing targeted therapies for diseases like cancer and diabetes. However, as highlighted in a recent analysis by The Hindu, India’s inconsistent biobank regulations threaten public trust and impede progress.

The Promise of Precision Medicine

In recent years, precision medicine has witnessed remarkable achievements. Through gene therapy, researchers have restored vision in individuals with genetic mutations, while in the U.K., scientists have reversed diabetes using reengineered stem cells. The rapid development of COVID-19 vaccines using the mRNA platform, which earned a Nobel Prize, further underscores the potential of precision medicine.

India’s Growing Market

The Indian precision medicine market is burgeoning, with projections estimating a value exceeding $5 billion by 2030. Initiatives like the BioE3 policy and the approval of NexCAR19, a domestically developed CAR-T cell therapy, mark significant strides. However, the true potential of these advancements lies in aligning biobank regulations with international standards.

The Biobank Conundrum

Biobank While countries like the U.K., U.S., and Japan have comprehensive biobank regulations ensuring data protection and privacy, India’s framework remains fragmented. The absence of a single authority to regulate biobanks and the lack of penalties for misconduct create risks of ethical violations and undermine public confidence. As the ICMR guidelines illustrate, participants often consent to provide samples without clarity on data usage, raising concerns about privacy and potential discrimination.

A Path Forward

To harness the full potential of precision medicine, India must establish stringent biobank regulations. Aligning with global standards will not only bolster public trust but also position India as a leader in next-generation therapeutics. As part of international groups like the Quad and BRICS, India has the opportunity to expand its pharmaceutical leadership and enhance its soft diplomatic efforts.

Manjeera Gowravaram, a PhD in RNA biochemistry, provides insightful analysis on the intersection of science and policy.

More Articles

Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!

Portable Mortgages Could Rewrite the Housing Market

The Trump administration is considering letting homeowners take their low mortgage rates with them when they move—a major shift that could ease inventory shortages but disrupt mortgage‑backed securities and raise legal challenges.

Washington Fines Mortgage Broker Over $60K in Major Compliance Crackdown

Washington State regulators issued more than $62,650 in penalties, fees, and restitution to a mortgage broker after uncovering widespread violations, including inaccurate call reports, 79 webpages missing mandatory disclosures, prohibited advertising language, unregistered trade names, and improper borrower preapprovals. The case serves as a crucial reminder for all mortgage, real estate, insurance, and finance professionals to stay vigilant with compliance as oversight continues to tighten nationwide.

The Real Cost of Owning a Home in 2025: Zillow’s New Report Shows a Price Surge Buyers Can’t Ignore

Hidden homeownership expenses are climbing fast, with Zillow revealing that Americans now pay nearly $16,000 a year in taxes, insurance, and maintenance—up sharply from previous years. Soaring premiums, especially in Florida, and rising upkeep costs are reshaping affordability, slowing sales, and creating new challenges for both first-time buyers and seasoned homeowners.

US Commercial Insurance Rates Shift in 2025 as Most Premiums Rise and Workers’ Comp Drops

The latest Ivans Index reveals a mixed but meaningful shift in the 2025 commercial insurance landscape, with most major coverages—including commercial auto, general liability, BOP, property, and umbrella—experiencing year‑over‑year premium increases. Workers’ compensation remains the lone category trending downward. Rising claims costs, reinsurance pressures, and market capacity changes continue to drive rates upward, while Ivans’ new Benchmarks tool brings real‑time pricing intelligence to insurers. For real estate, insurance, mortgage, and business professionals, staying informed on these changes is key to planning, budgeting, and managing risk in the year ahead.

Mortgage Rates Dip as 50-Year Loan Proposal Sparks Big Market Reactions

This week’s mortgage update brought only a slight rate decline, but a much bigger conversation: the possibility of a 50-year mortgage. While a longer term could lower monthly payments by about $130 on a typical $400,000 loan, experts warn it would add more than $500,000 in extra interest and dramatically slow equity growth. With inflation still elevated and the Fed’s next moves uncertain, mortgage rates may edge higher heading into the season. Real estate and mortgage professionals should be ready to address client questions as this ultra-long loan idea gains attention, especially in markets like Florida where affordability remains tight.

LKP Finance’s Profit, Legal Battles, and Surprise Rebrand: A Wake‑Up Call for Today’s Professionals

LKP Finance reported a solid Rs 583.15‑lakh profit for Q2 2025 — but beneath the surface lies a storm of leadership changes, litigation over multi‑crore debts, a rare 12‑year‑old loan write‑back, and a full corporate transformation into Gyftr Limited. From compliance shake‑ups to a dramatic pivot into digital gifting and fintech, this quarter offers big lessons for professionals navigating fast‑evolving industries.